Dipeptidyl peptidase-4 inhibitors, which reduce systemic inflammation and improve metabolic health, may improve psoriasis severity and may also provide an opportunity to treat, and prevent, major comorbidities. This evidence concerns the gene DPP4 and psoriasis.